Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified Activin A and follistatin as key regulators of hair cell differentiation in the mammalian auditory sensory epithelium, with Activin A signaling influencing the timing and pattern of cell differentiation.

This review discusses the similarities between myotonic dystrophy and aging, highlighting the role of cellular senescence in its pathophysiology, and reports no new clinical findings; the authors note potential anti-aging therapy applications.

This study presents an improved protocol for isolating and culturing whole neonatal cochlear explants, enabling detailed analysis of hair cells and spiral ganglion neuron cells while simplifying culture steps without sacrificing explant quality, and was successfully tested on mice and rat cochleas.

In this study, researchers investigated age-related hearing loss in advanced-age CBA/CaJ mice and found combined cochlear damage from chronic sound exposure and metabolic changes linked to oxidative stress, which may require addressing both etiologies for prevention and treatment.

In this study, researchers evaluated hair follicle transplantation techniques and reported that challenges such as limited follicle supply and low follicle survival rates often limit patient satisfaction, but advances in regenerative medicine may offer promising new solutions.

Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.

In this study, significant elevations of DHA and testosterone were associated with pubic hair development and voice changes in boys during puberty.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

This study found that topical application of hair lotion containing 17α-estradiol may reduce androgenetic hair loss, as 63% of treated patients showed a decrease in telogen hairs compared to 37% in the control group.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This case study reported that absence of alopecia does not reliably predict responsiveness to vitamin D treatment in Vitamin D-dependent rickets type II, as demonstrated by a patient with normal hair growth who showed extreme resistance.

In this study, researchers identified and examined males with 17 beta-HSD3 deficiency in a highly inbred Arab population, noting genetic findings and the progression of male characteristics despite being raised as females initially.

This study found that women with PCOS who have an exaggerated 17-hydroxyprogesterone response to buserelin exhibit more severe hyperandrogenemia, increased insulin secretion, and reduced insulin sensitivity.

This study found that topical hair lotions with 17 alpha-estradiol may reduce telogen hair loss in patients with androgenetic alopecia, though they did not lead to new hair regrowth.

This study found that the effectiveness of 17-beta-estradiol in inhibiting hair growth depends on its application method, and noted significant sex differences in response to 17-alpha-estradiol in male and female mice.

This article reviews the potential neuroprotective effects of 17α‐estradiol in neurodegenerative diseases and highlights its possibly lower toxicity compared to more feminizing hormones, but it reports no new clinical findings.

This study found that diagnosing nonclassic congenital adrenal hyperplasia in women based solely on serum 17OHP measurements can lead to false positives, suggesting the need for urinary steroid profiles and genetic testing for confirmation.

17-β estradiol and prednisolone may speed up hair regrowth after chemotherapy.

This study shows that measuring 17-hydroxyprogesterone concentrations in scalp hair may be a useful noninvasive tool for monitoring treatment in adults with congenital adrenal hyperplasia.

This study found that 1,550-nm Er:Glass fractional laser treatment increased hair density and shaft diameter in patients with androgenetic alopecia, but did not up-regulate Wnt10A and IGF-1 mRNA expression.

This study suggests that measuring scalp hair 17-hydroxyprogesterone and androstenedione concentrations can be a promising tool for monitoring treatment in children with congenital adrenal hyperplasia.

This case report describes a woman with hyperandrogenism and menstrual disturbances, where an ovarian steroid cell tumor was identified and removed, leading to resolution of symptoms.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study found that spironolactone reduced androgenic hormones in hirsute women but had only marginal effects on hair growth, making it no more advisable than other therapies.

This study found that glioblastoma cells express key enzymes involved in androgen synthesis, suggesting these enzymes might be potential targets for new therapeutic strategies.

This case study reports an Asian female with congenital adrenal hyperplasia presenting atypically with polymenorrhagia, who showed improvement with oral dexamethasone, despite no change in hirsutism or clitoromegaly.

In this case report, researchers describe a 13-year-old phenotypic female with 46,XY karyotype, previously misdiagnosed with androgen insensitivity syndrome, who was later identified to have 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, underscoring the importance of genetic and hormonal tests for accurate diagnosis of sex development disorders.

This study evaluated the stability of multiple active ingredients in TrichoSol™ for use in alopecia treatments, finding varying stability durations at room temperature—up to 180 days for some ingredients—supporting its use as a compounding vehicle in personalized therapies.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.